Tags

Type your tag names separated by a space and hit enter

The Affordable Medicines Facility-malaria--a success in peril.
Malar J. 2012 Nov 08; 11:370.MJ

Abstract

The Affordable Medicines Facility-malaria (AMFm) has put into place a bold financing plan for artemisinin-combination therapy in a pilot phase in seven countries covering half the population at risk of malaria in Africa. A report of the AMFm independent evaluation, conducted by ICF International and the London School of Hygiene and Tropical Medicine, describes the success of the programme in the pilot sites: Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania (mainland and Zanzibar) and Uganda, comparing availability and affordability of high-quality artemisinin-combination therapies before and after AMFm launched. Proof of concept was achieved: AMFm increased availability and kept prices low, meeting its initial, ambitious benchmarks in most settings. Despite this overwhelming success, opposition to the programme and dwindling resources for malaria control conspire to cripple or kill AMFm.

Authors+Show Affiliations

World Wide Antimalarial Resistance Network (WWARN), Malaria Public Health Department, University of Oxford/KEMRI/Wellcome Trust Research Programme, PO Box 43640, 00100, Nairobi, Kenya. atalisuna@nairobi.kemri-wellcome.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Editorial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23137141

Citation

Talisuna, Ambrose O., et al. "The Affordable Medicines Facility-malaria--a Success in Peril." Malaria Journal, vol. 11, 2012, p. 370.
Talisuna AO, Adibaku S, Amojah CN, et al. The Affordable Medicines Facility-malaria--a success in peril. Malar J. 2012;11:370.
Talisuna, A. O., Adibaku, S., Amojah, C. N., Amofah, G. K., Aubyn, V., Dodoo, A., Juma, E., Jackou, D. H., Mkude, S., Okui, A. P., Ramarosandratana, B., & Shija, S. J. (2012). The Affordable Medicines Facility-malaria--a success in peril. Malaria Journal, 11, 370. https://doi.org/10.1186/1475-2875-11-370
Talisuna AO, et al. The Affordable Medicines Facility-malaria--a Success in Peril. Malar J. 2012 Nov 8;11:370. PubMed PMID: 23137141.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Affordable Medicines Facility-malaria--a success in peril. AU - Talisuna,Ambrose O, AU - Adibaku,Seraphine, AU - Amojah,Chioma N, AU - Amofah,George K, AU - Aubyn,Vivian, AU - Dodoo,Alex, AU - Juma,Elizabeth, AU - Jackou,Djermakoye H, AU - Mkude,Sigsbert, AU - Okui,Albert P, AU - Ramarosandratana,Benjamin, AU - Shija,Shija J, Y1 - 2012/11/08/ PY - 2012/11/02/received PY - 2012/11/05/accepted PY - 2012/11/10/entrez PY - 2012/11/10/pubmed PY - 2013/4/30/medline SP - 370 EP - 370 JF - Malaria journal JO - Malar J VL - 11 N2 - The Affordable Medicines Facility-malaria (AMFm) has put into place a bold financing plan for artemisinin-combination therapy in a pilot phase in seven countries covering half the population at risk of malaria in Africa. A report of the AMFm independent evaluation, conducted by ICF International and the London School of Hygiene and Tropical Medicine, describes the success of the programme in the pilot sites: Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania (mainland and Zanzibar) and Uganda, comparing availability and affordability of high-quality artemisinin-combination therapies before and after AMFm launched. Proof of concept was achieved: AMFm increased availability and kept prices low, meeting its initial, ambitious benchmarks in most settings. Despite this overwhelming success, opposition to the programme and dwindling resources for malaria control conspire to cripple or kill AMFm. SN - 1475-2875 UR - https://www.unboundmedicine.com/medline/citation/23137141/The_Affordable_Medicines_Facility_malaria__a_success_in_peril_ L2 - https://malariajournal.biomedcentral.com/articles/10.1186/1475-2875-11-370 DB - PRIME DP - Unbound Medicine ER -